BCG vaccine
This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.
Identification
- Summary
BCG vaccine is a vaccine indicated in the prevention of tuberculosis and the treatment of non-invasive urothelial bladder cancer.
- Generic Name
- BCG vaccine
- DrugBank Accession Number
- DB12768
- Background
BCG vaccine has been investigated for the treatment of Neoplasms, Bladder Cancer, Neoplasms by Site, Urologic Diseases, and Urologic Neoplasms, among others.
- Type
- Biotech
- Groups
- Approved, Investigational
- Biologic Classification
- Vaccines
Attenuated - Synonyms
- Bacillus calmette-guerin live antigen, unspecified substrain
- Bacillus Calmette–Guérin (BCG) vaccine
- BCG
- BCG vaccine
Pharmacology
- Indication
Not Available
Accelerate your drug discovery research with the industry’s only fully connected ADMET dataset, ideal for:Accelerate your drug discovery research with our fully connected ADMET dataset- Associated Conditions
- Contraindications & Blackbox Warnings
Contraindications & Blackbox WarningsWith our commercial data, access important information on dangerous risks, contraindications, and adverse effects.Our Blackbox Warnings cover Risks, Contraindications, and Adverse Effects- Pharmacodynamics
Not Available
- Mechanism of action
- Not Available
- Absorption
Not Available
- Volume of distribution
Not Available
- Protein binding
Not Available
- Metabolism
- Not Available
- Route of elimination
Not Available
- Half-life
Not Available
- Clearance
Not Available
- Adverse Effects
Reduce medical errorsand improve treatment outcomes with our comprehensive & structured data on drug adverse effects.Reduce medical errors & improve treatment outcomes with our adverse effects data- Toxicity
Not Available
- Pathways
- Not Available
- Pharmacogenomic Effects/ADRs
- Not Available
Interactions
- Drug Interactions
- This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
Drug Interaction Integrate drug-drug
interactions in your softwareAbacavir The therapeutic efficacy of BCG vaccine can be decreased when used in combination with Abacavir. Abatacept The risk or severity of infection can be increased when BCG vaccine is combined with Abatacept. Acetic acid The therapeutic efficacy of BCG vaccine can be decreased when used in combination with Acetic acid. Acetyl sulfisoxazole The therapeutic efficacy of BCG vaccine can be decreased when used in combination with Acetyl sulfisoxazole. Acyclovir The therapeutic efficacy of BCG vaccine can be decreased when used in combination with Acyclovir. Adalimumab The risk or severity of infection can be increased when BCG vaccine is combined with Adalimumab. Adefovir dipivoxil The therapeutic efficacy of BCG vaccine can be decreased when used in combination with Adefovir dipivoxil. Aldesleukin The risk or severity of infection can be increased when BCG vaccine is combined with Aldesleukin. Alefacept The risk or severity of infection can be increased when BCG vaccine is combined with Alefacept. Alemtuzumab The risk or severity of infection can be increased when BCG vaccine is combined with Alemtuzumab. 
Improve patient outcomesBuild effective decision support tools with the industry’s most comprehensive drug-drug interaction checker.Learn more - Food Interactions
- Not Available
Products
Comprehensive & structured drug product infoFrom application numbers to product codes, connect different identifiers through our commercial datasets.Easily connect various identifiers back to our datasets
Categories
- ATC Codes
- L03AX03 — Bcg vaccine
- Drug Categories
- Classification
- Not classified
- Affected organisms
- Not Available
Chemical Identifiers
- UNII
- XZQ806VFEO
- CAS number
- Not Available
References
- General References
- External Links
- PubChem Substance
- 347911376
- 1344
- Wikipedia
- BCG_vaccine
Clinical Trials
- Clinical Trials
Phase Status Purpose Conditions Count 4 Active Not Recruiting Prevention Coronavirus Disease 2019 (COVID‑19) 1 4 Completed Basic Science Adverse Reaction to Vaccine / Heterologous Immunity / Infant Morbidity / Mortality, Infant / Trained Immunity / Vaccine Reaction 1 4 Completed Diagnostic Tuberculosis (TB) 1 4 Completed Prevention BCG Infection / Immune Response / Vaccine Reaction 1 4 Completed Prevention Chronic Obstructive Pulmonary Disease (COPD) / Coronary Heart Disease (CHD) / Coronavirus Disease 2019 (COVID‑19) / Infections, Coronavirus / Virus Diseases 1 4 Completed Prevention Clinical / Intervention / Prospective / Single-blind / Trial 1 4 Completed Prevention Tuberculosis (TB) 1 4 Recruiting Prevention Absenteeism / Coronavirus Disease 2019 (COVID‑19) / Morbidity 1 4 Recruiting Prevention BCG Vaccination Reaction / Mother-Infant Interaction / Rubeola / Vaccine Preventable Disease 1 4 Recruiting Prevention BCG / Mortality, Infant 1
Pharmacoeconomics
- Manufacturers
- Not Available
- Packagers
- Not Available
- Dosage Forms
Form Route Strength Solution Intravesical Powder, for solution Intravesical Powder, for suspension Intravesical Injection, powder, lyophilized, for solution Intravesical Injection, powder, for suspension Intradermal Powder Intravesical Injection, powder, lyophilized, for solution Intradermal Injection Intradermal Injection, powder, lyophilized, for suspension Intravesical Injection, powder, for solution Intravesical Injection Intradermal 81 mg/1vial - Prices
- Not Available
- Patents
- Not Available
Properties
- State
- Not Available
- Experimental Properties
- Not Available
Drug created on October 21, 2016 00:07 / Updated on June 12, 2021 10:54